← brief for 2026-09-17 · Slowing decline

Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This review pooled 10 sets of randomized trial data from adults with type 2 diabetes and kidney disease. It compared four options for protecting the kidneys and heart: finerenone, SGLT2 inhibitor drugs, semaglutide, and finerenone taken with an SGLT2 inhibitor. It also compared their side effects. The part of the summary we received cuts off before the results, so we cannot yet say which option did best or by how much.

Who did this work

Zhou Z · Fu L · Chen D · Yu P · Xu G · Wu Q · Wu T · Yang P

Source

Article · PubMed, the drug frontier · 2026 Sep 17
https://pubmed.ncbi.nlm.nih.gov/42750649/